All Posts Tagged With: "TEVA"
(MYL) Mylan Launches New Generic Pharmaceuticals
Mylan Inc.’s (MYL) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical’s pain reliever Roxicodone. The generic has been launched under a development...
(MYL) Mylan Launches Generic Drugs
MylanInc. (MYL) recently launched its generic version of Ista Pharmaceuticals Inc’s (ISTA) Xibrom ophthalmic solution,...
(VRX) Valeant Pharmaceuticals Beats Earnings Estimates on Revenues
Valeant Pharmaceuticals International‘s (VRX) first quarter 2011 earnings of 49 cents per share (excluding special items but including stock-based compensation expense) missed the Zacks Consensus Estimate...
(PRGO) Perrigo Cruises Past Estimates – Lifts Outlook
Perrigo Company (PRGO) reported earnings per share of $1.07 for the third quarter of fiscal 2011, easily beating the Zacks Consensus Estimate of 96 cents and the year-earlier earnings of 81 cents per share....
(ABT) Abbott Laboratories Earns FDA Approval of AndroGel
Abbott Laboratories (ABT) recently gained US Food and Drug Administration (FDA) approval for AndroGel (testosterone gel) 1.62%. The gel formulation is approved for the treatment of hypogonadism (low or zero...
(CEPH) Cephalon First Quarter 2011 Earnings Miss Expectations
Cephalon Inc. (CEPH) delivered first quarter earnings of $1.98 per share, several cents below the Zacks Consensus Estimate of $2.04 but 12.5% above the year-ago earnings of $1.76.
First quarter revenues,...
(TEVA) Teva Pharmaceutical Industries Announces Aquisition of Cephalon
Yet another acquisition deal was announced in the pharma sector with generic player, Teva Pharmaceutical Industries Ltd. (TEVA) entering into a definitive agreement with Cephalon, Inc. (
(MYL) Mylan Meets Analyst Estimates – Sales Upbeat
Mylan Inc.’s (MYL) first quarter 2011 earnings (excluding special items) of 44 cents per share were in line with the Zacks Consensus Estimate. A higher quarterly tax rate, increased share count and pricing...
(AA) Company News for May 03, 2011 – Corporate Summary
• Arch Coal, Inc. (NYSE:ACI) and International Coal Group, Inc. (NYSE:ICO) announced that they have signed a definitive agreement under which Arch will acquire all...
(CEPH) Stock Market News for May 3, 2011 – Market News
Late on Sunday, US President Barack Obama declared: “I determined that we had enough intelligence to take action and authorized an operation to get Osama bin Laden and bring him to justice….After a firefight, they killed Osama bin Laden and took custody of his body.”...
(BIIB) Biogen Idec Earnings Above Estimates on Multiple Sclerosis Drugs
Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based...
(BIIB) Biogen Idec Earnings Report Beats The Street
Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based...
(BIIB) Biogen’s Oral Multiple Sclerosis Drug Impresses
Biogen (BIIB) received a boost recently with the company presenting promising top-line data on its oral multiple sclerosis candidate, BG-12. The company presented positive results on the use of BG-12 as a...
(PRGO) Perrigo Resolves Manufacturing Issues with FDA
Perrigo Company (PRGO) recently announced the resolution of manufacturing issues at its Allegan, Michigan facility with the US Food and Drug Administration (FDA) following conclusion of re-inspection of the...
(AZN) AstraZeneca Drug Vandetanib Earns FDA Approval
AstraZeneca (AZN) recently gained US Food and Drug Administration (FDA) approval for its orphan drug vandetanib for the treatment of non-operable (unresectable) locally advanced or metastatic medullary thyroid...
(LLY) Eli Lilly’s Axiron Testosterone Deficiency Drug Launched in the U.S.
Eli Lilly and Company (LLY) recently announced the availability of Axiron in pharmacies across the US. Axiron gained approval from the US Food and Drug Administration (FDA) in November 2010 for use as a replacement...
(MYL) Mylan Analyst Maintains Neutral Rating on Shares
We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $23.00 after appraising fourth quarter and fiscal year 2010 financial results.
Mylan’s fourth quarter 2010...
(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were...
(TEVA) Teva Pharmaceutical Industries Earnings Miss Forecast – Guidance Falls Short
Teva Pharmaceutical Industries’ (TEVA) fourth quarter earnings of $1.25 per American Depository Share (ADS) missed the Zacks Consensus Estimate of $1.28. Earnings, however, increased 32.9% from the year-ago...
(AVP) Stock Market News for Febuary 09, 2011
On Tuesday, markets gained points with the Dow closing higher for the seventh consecutive session, the longest run of gains since July, helped by strong sales figures posted by Mc Donald’s. However, the gains were limited by falling energy prices which were hit by China’s...
(BIIB) Biogen Quarterly Earnings Report Beats by a Wide Margin
Biogen Idec (BIIB) reported fourth-quarter earnings per share of $1.41, well above the Zacks Consensus Estimate of $1.23 and the year-earlier figure of $1.18. Excluding the impact of stock-based compensation...
(SIGA) These Healthcare Stocks Are Ready to Move Next Week
by Marc Lichtenfeld, Investment U’s Senior Analyst
Wednesday,...
(LLY) Eli Lilly and Company Gets FDA Approval of Axiron
Eli Lilly and Company (LLY) and partner Acrux recently announced good news in the form of US Food and Drug Administration (FDA) approval for Axiron. The FDA approved Axiron for use as a replacement therapy...
(MDCO) The Medicines Company Receives Good Patent News
We recently reiterated our Outperform recommendation on The Medicines Company (MDCO). In August 2010, The Medicines Company received good news with the US District Court for the Eastern District of Virginia...
(TEVA) Teva Pharmaceutical Industries Beats The Street on Earnings
Teva Pharmaceutical Industries’ (TEVA) third quarter earnings of $1.30 per American Depository Share (ADS) were above the Zacks Consensus Estimate of $1.27 and the year-ago earnings of 89 cents.
Teva’s...
(CEPH) Cephalon Reports Very Strong Quarterly Earnings
Cephalon, Inc. (CEPH) delivered another strong quarter with earnings coming at $2.14 per share, easily beating the Zacks Consensus Estimate of $1.79 and well above the year-ago earnings of $1.62.
Strong...
(SNY) Sanofi-Aventis Presents Encouraging Data on MS Drug
French pharmaceutical company, Sanofi-Aventis (SNY) recently presented encouraging results on its multiple sclerosis (MS) candidate, teriflunomide. Results from a phase III randomized, double-blind, placebo-controlled...
(LLY) Eli Lilly’s Alimta Disappoints for Oncology Pipeline
Eli Lilly’s (LLY) oncology pipeline suffered a setback recently with the company reporting disappointing results on Alimta from a phase III study. Data, presented at the annual meeting of the European Society...
(TEVA) Teva Pharmaceuticals Industries Oncology Drug Progresses
Teva Pharmaceuticals Industries Ltd. (TEVA) and OncoGenex Pharmaceuticals, Inc. (OXGI) recently announced that they have initiated a second...
(TEVA) Teva Pharmaceutical Industries Learns Drug Approval Delayed
Teva Pharmaceutical Industries Ltd.’s (TEVA) Neutroval failed to receive first-round approval in the US with the Food and Drug Administration (FDA) recently issuing a complete response letter (CRL) for...